{"title":"地高辛——一种有效的抗癫痫药。","authors":"I V Markova, I B Mikhaĭlov, V I Guzeva","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A new pathogenetically grounded approach to the treatment of resistant forms of epilepsy is proposed. Digoxin suppresses the activity of experimental epileptogenic foci produced in the hippocampus of animals (frogs and rats) and also convulsions induced by corazol, bemegrid or electroshock. The antiepileptic and anticonvulsant activity of the drug was confirmed during its clinical testing on 20 children with grave forms of epilepsy which were resistant to the known antiepileptic drugs. The positive therapeutic effect was obtained in 42% of the cases.</p>","PeriodicalId":12237,"journal":{"name":"Farmakologiia i toksikologiia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"1991-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Digoxin--an active antiepileptic agent].\",\"authors\":\"I V Markova, I B Mikhaĭlov, V I Guzeva\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A new pathogenetically grounded approach to the treatment of resistant forms of epilepsy is proposed. Digoxin suppresses the activity of experimental epileptogenic foci produced in the hippocampus of animals (frogs and rats) and also convulsions induced by corazol, bemegrid or electroshock. The antiepileptic and anticonvulsant activity of the drug was confirmed during its clinical testing on 20 children with grave forms of epilepsy which were resistant to the known antiepileptic drugs. The positive therapeutic effect was obtained in 42% of the cases.</p>\",\"PeriodicalId\":12237,\"journal\":{\"name\":\"Farmakologiia i toksikologiia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1991-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Farmakologiia i toksikologiia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Farmakologiia i toksikologiia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A new pathogenetically grounded approach to the treatment of resistant forms of epilepsy is proposed. Digoxin suppresses the activity of experimental epileptogenic foci produced in the hippocampus of animals (frogs and rats) and also convulsions induced by corazol, bemegrid or electroshock. The antiepileptic and anticonvulsant activity of the drug was confirmed during its clinical testing on 20 children with grave forms of epilepsy which were resistant to the known antiepileptic drugs. The positive therapeutic effect was obtained in 42% of the cases.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
